DBV Technologies reported 0 in Debt for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Debt Change
DBV Technologies DBVT:US 0 0
Acadia Pharmaceuticals ACAD:US $ 0M 0M
Alnylam Pharmaceuticals ALNY:US $ 677.72M 1.01M
Amarin AMRN:US $ 0M 0M
Biocryst Pharmaceuticals BCRX:US $ 622.18M 17.72M
Biomarin Pharmaceutical BMRN:US $ 1081.05M 0.99M
Eleven Biotherapeutics EBIO:US $ 0M 0M
Esperion Therapeutics ESPR:US $ 259.08M 402K
Galectin Therapeutics GALT:US $ 29.5M 0.23M
Halozyme Therapeutics HALO:US $ 1246.18M 368.53M
Insmed INSM:US $ 807.32M 534K
Intercept Pharmaceuticals ICPT:US $ 713.86M 3.03M
IONIS PHARMACEUT IONS:US $ 1253.13M 1M
Neurocrine Biosciences NBIX:US $ 169M 208.7M
Ptc Therapeutics PTCT:US $ 1207.54M 10.46M
Sarepta Therapeutics SRPT:US $ 1100.87M 2.03M
Ultragenyx Pharmaceutical RARE:US $ 0M 0M
United Therapeutics UTHR:US $ 800M 0M
YTE INCY:US $ 34.19M 0.01M